Physician profile
Jay Diaz
NPI 1992282313
$648.37
in general payments reported to CMS, 2019-2025
15 companies · $98.89 in 2025
The $98.89 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.00 · 2023: $483 · 2024: $54.59 · 2025: $98.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.37 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $145.45 | 2023 | Darzalex, Tecvayli, Imbruvica |
| Novartis Pharmaceuticals Corporation | $111.79 | 2023-2024 | |
| Lilly USA, LLC | $66.37 | 2023 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $61.02 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $45.21 | 2023-2025 | Lynparza, Keytruda, Bridion |
| Abbvie INC. | $44.07 | 2024-2025 | |
| Celgene Corporation | $26.35 | 2023 | Pomalyst |
| Incyte Corporation | $23.48 | 2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $22.36 | 2023 | Alunbrig |
| Ipsen Biopharmaceuticals, INC | $20.47 | 2023 | Onivyde, Somatuline Depot |
| Genmab U.S., INC. | $20.46 | 2023 | Epkinly |
| Amneal Pharmaceuticals LLC | $17.20 | 2025 | Alymsys |
| Jazz Pharmaceuticals INC. | $16.45 | 2025 | |
| Daiichi Sankyo INC. | $15.69 | 2025 | Enhertu |
| Boston Scientific Corporation | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.